albizziin: RN given refers to parent cpd without isomeric designation; structure
ID Source | ID |
---|---|
PubMed CID | 92891 |
CHEBI ID | 6173 |
SCHEMBL ID | 690347 |
MeSH ID | M0049023 |
Synonym |
---|
nsc-132089 |
albizzine |
l-albizziin |
l-alanine, 3-[(aminocarbonyl)amino]- |
l-2-amino-3-ureidopropionic acid |
C08264 |
albizziin |
l-albizziine |
1483-07-4 |
A-4650 |
zinc01531037 |
(2s)-2-amino-3-(carbamoylamino)propanoic acid |
A808754 , |
(s)-2-amino-3-ureidopropanoicacid |
AKOS006237907 |
3-ureido-l-alanin |
l-alanine, 3-((aminocarbonyl)amino)- |
albizziin (van) |
nsc 132089 |
einecs 216-046-1 |
l-beta-ureidoalanine |
rw59as48cr , |
unii-rw59as48cr |
l-(-)-2-amino-3-ureidopropionic acid |
propionic acid, 2-amino-3-ureido-, l- |
nsc 407273 |
albizziin [mi] |
3-((aminocarbonyl)amino)-l-alanine |
SCHEMBL690347 |
CHEBI:6173 |
(2s)-2-amino-3-ureido-propanoic acid |
3-[(aminocarbonyl)amino]alanine # |
GZYFIMLSHBLMKF-REOHCLBHSA-N |
(2s)-2-ammonio-3-(carbamoylamino)propanoate |
(2s)-3-(aminocarbonylamino)-2-azaniumyl-propanoate |
c4h9n3o3 |
albizziin (h-dap(conh2)-oh) |
mfcd00007952 |
l-(-)2-amino-3-ureidopropionic acid |
h-beta-(ureido)-ala-oh |
AS-63003 |
C90278 |
albizziin, aldrichcpr |
h--((aminocarbonyl)amino)-ala-oh;h-dap(carbamoyl)-oh |
(s)-2-amino-3-ureidopropanoic acid |
Q27107112 |
AMY22571 |
HY-121167 |
butyl 4-?hydroxybenzoate |
(butyl paraben) |
DTXSID501318659 |
EN300-7026825 |
CS-0079579 |
nsc823850 |
nsc-823850 |
Class | Description |
---|---|
non-proteinogenic L-alpha-amino acid | Any L-alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (57.14) | 18.7374 |
1990's | 3 (42.86) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Condition | Indicated | Relationship Strength | Studies | Trials |
---|---|---|---|---|
Abnormalities, Autosome | 0 | low | 1 | 0 |
Abnormalities, Chromosomal | 0 | low | 1 | 0 |
Abnormalities, Chromosome | 0 | low | 1 | 0 |
Aging | 0 | low | 1 | 0 |
Autosome Abnormalities | 0 | low | 1 | 0 |
Chromosomal Aberrations | 0 | low | 1 | 0 |
Chromosome Aberrations | 0 | low | 1 | 0 |
Chromosome Abnormalities | 0 | low | 1 | 0 |
Cytogenetic Aberrations | 0 | low | 1 | 0 |
Cytogenetic Abnormalities | 0 | low | 1 | 0 |